Literature DB >> 20511445

Lipoprotein(a) and risk of type 2 diabetes.

Samia Mora1, Pia R Kamstrup, Nader Rifai, Børge G Nordestgaard, Julie E Buring, Paul M Ridker.   

Abstract

BACKGROUND: Previous studies have demonstrated that cardiovascular risk is higher with increased lipoprotein(a) [Lp(a)]. Whether Lp(a) concentration is related to type 2 diabetes is unclear.
METHODS: In 26 746 healthy US women (mean age 54.6 years), we prospectively examined baseline Lp(a) concentrations and incident type 2 diabetes (n = 1670) for a follow-up period of 13 years. We confirmed our findings in 9652 Danish men and women with prevalent diabetes (n = 419). Analyses were adjusted for risk factors that included age, race, smoking, hormone use, family history, blood pressure, body mass index, hemoglobin A(1c) (Hb A(1c)), C-reactive protein, and lipids.
RESULTS: Lp(a) was inversely associated with incident diabetes, with fully adjusted hazard ratios (HRs) and 95% CIs for quintiles 2-5 vs quintile 1 of 0.87 (0.75-1.01), 0.80 (0.68-0.93), 0.88 (0.76-1.02), and 0.78 (0.67-0.91); P for trend 0.002. The association was stronger in nonfasting women, for whom respective HRs were 0.79 (0.58-1.09), 0.78 (0.57-1.08), 0.66 (0.46-0.93), and 0.56 (0.40-0.80); P for trend 0.001; P for interaction with fasting status 0.002. When we used Lp(a) > or =10 mg/L and Hb A(1c) <5% as reference values, the adjusted HRs were 1.62 (0.91-2.89) for Lp(a) <10 mg/L and Hb A(1c) <5%, 3.50 (3.06-4.01) for Lp(a) > or =10 mg/L and Hb A(1c) 5%-<6.5%, and 5.36 (4.00-7.19) for Lp(a) <10 mg/L and Hb A(1c) 5%-<6.5%. Results were similar in nonfasting Danish men and women, for whom adjusted odds ratios were 0.75 (0.55-1.03), 0.64 (0.46-0.88), 0.74 (0.54-1.01), and 0.58 (0.42-0.79) for Lp(a) quintiles 2-5 vs quintile 1; P for trend 0.002.
CONCLUSIONS: Our results indicated that Lp(a) was associated inversely with risk of type 2 diabetes independently of risk factors, in contrast to prior findings of positive associations of Lp(a) with cardiovascular risk.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20511445      PMCID: PMC2912456          DOI: 10.1373/clinchem.2010.146779

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  24 in total

1.  Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III).

Authors: 
Journal:  JAMA       Date:  2001-05-16       Impact factor: 56.272

2.  Use of a reference material proposed by the International Federation of Clinical Chemistry and Laboratory Medicine to evaluate analytical methods for the determination of plasma lipoprotein(a).

Authors:  S M Marcovina; J J Albers; A M Scanu; H Kennedy; F Giaculli; K Berg; R Couderc; F Dati; N Rifai; I Sakurabayashi; J R Tate; A Steinmetz
Journal:  Clin Chem       Date:  2000-12       Impact factor: 8.327

Review 3.  The relationship between lipoprotein(a) and the complications of diabetes mellitus.

Authors:  M L Koschinsky; S M Marcovina
Journal:  Acta Diabetol       Date:  2003-06       Impact factor: 4.280

4.  Plasma apolipoprotein (a) is increased in type 2 (non-insulin-dependent) diabetic patients with microalbuminuria.

Authors:  A J Jenkins; J S Steele; E D Janus; J D Santamaria; J D Best
Journal:  Diabetologia       Date:  1992-11       Impact factor: 10.122

5.  Association of elevated lipoprotein(a) levels and coronary heart disease in NIDDM patients. Relationship with apolipoprotein(a) phenotypes.

Authors:  J Ruiz; J Thillet; T Huby; R W James; D Erlich; P Flandre; P Froguel; J Chapman; P Passa
Journal:  Diabetologia       Date:  1994-06       Impact factor: 10.122

6.  Lp(a) concentrations in NIDDM.

Authors:  S M Haffner; P A Morales; M P Stern; M K Gruber
Journal:  Diabetes       Date:  1992-10       Impact factor: 9.461

7.  Insulin-like growth factor-I improves glucose and lipid metabolism in type 2 diabetes mellitus.

Authors:  P D Zenobi; S E Jaeggi-Groisman; W F Riesen; M E Røder; E R Froesch
Journal:  J Clin Invest       Date:  1992-12       Impact factor: 14.808

8.  Prospective study of lipoprotein(a) as a risk factor for atherosclerotic cardiovascular disease in patients with diabetes.

Authors:  T Hiraga; T Kobayashi; M Okubo; K Nakanishi; T Sugimoto; Y Ohashi; T Murase
Journal:  Diabetes Care       Date:  1995-02       Impact factor: 19.112

9.  Effects of NIDDM on lipoprotein(a) concentration and apolipoprotein(a) size.

Authors:  D L Rainwater; J W MacCluer; M P Stern; J L VandeBerg; S M Haffner
Journal:  Diabetes       Date:  1994-07       Impact factor: 9.461

10.  Growth hormone treatment of growth hormone-deficient adults results in a marked increase in Lp(a) and HDL cholesterol concentrations.

Authors:  S Edén; O Wiklund; J Oscarsson; T Rosén; B A Bengtsson
Journal:  Arterioscler Thromb       Date:  1993-02
View more
  64 in total

1.  Lipoprotein(a) in type 2 diabetic subjects and its relationship to diabetic microvascular complications.

Authors:  Radhakrishnan Chandni; Kollengode Parameswaran Ramamoorthy
Journal:  World J Diabetes       Date:  2012-05-15

Review 2.  Causes and consequences of lipoprotein(a) abnormalities in kidney disease.

Authors:  Florian Kronenberg
Journal:  Clin Exp Nephrol       Date:  2013-10-16       Impact factor: 2.801

3.  Long-term statin therapy could be efficacious in reducing the lipoprotein (a) levels in patients with coronary artery disease modified by some traditional risk factors.

Authors:  Ming-Xing Xu; Chang Liu; Yong-Ming He; Xiang-Jun Yang; Xin Zhao
Journal:  J Thorac Dis       Date:  2017-05       Impact factor: 2.895

4.  Serum lipoprotein (a) concentrations are inversely associated with T2D, prediabetes, and insulin resistance in a middle-aged and elderly Chinese population.

Authors:  Lin Ding; An Song; Meng Dai; Min Xu; Wanwan Sun; Baihui Xu; Jichao Sun; Tiange Wang; Yu Xu; Jieli Lu; Weiqing Wang; Yufang Bi; Guang Ning
Journal:  J Lipid Res       Date:  2015-02-03       Impact factor: 5.922

5.  Lipoprotein(a), type 2 diabetes and nephropathy; the mystery continues.

Authors:  Azar Baradaran
Journal:  J Nephropathol       Date:  2012-10-01

Review 6.  Structure, function, and genetics of lipoprotein (a).

Authors:  Konrad Schmidt; Asma Noureen; Florian Kronenberg; Gerd Utermann
Journal:  J Lipid Res       Date:  2016-04-13       Impact factor: 5.922

Review 7.  Insight into rheumatological cause and effect through the use of Mendelian randomization.

Authors:  Philip C Robinson; Hyon K Choi; Ron Do; Tony R Merriman
Journal:  Nat Rev Rheumatol       Date:  2016-07-14       Impact factor: 20.543

Review 8.  Lipoprotein (a) as a cause of cardiovascular disease: insights from epidemiology, genetics, and biology.

Authors:  Børge G Nordestgaard; Anne Langsted
Journal:  J Lipid Res       Date:  2016-09-27       Impact factor: 5.922

9.  LPA kringle IV type 2 is associated with type 2 diabetes in a Chinese population with very high cardiovascular risk.

Authors:  Di-Li-Da-Er Mu-Han-Ha-Li 迪丽达尔 木汗哈力; Tian-Yu Zhai 翟天羽; Yan Ling 凌雁; Xin Gao 高鑫
Journal:  J Lipid Res       Date:  2018-03-06       Impact factor: 5.922

10.  In search of a physiological function of lipoprotein(a): causality of elevated Lp(a) levels and reduced incidence of type 2 diabetes.

Authors:  Sotirios Tsimikas
Journal:  J Lipid Res       Date:  2018-04-02       Impact factor: 5.922

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.